Products

Human SARS-CoV-2 Nucleocapsid ELISA Kit
ECV001
Size: Price:
48 T $320.00
96 T $458.00

Overview

Product name: Human SARS-CoV-2 Nucleocapsid ELISA Kit
Reactivity: Human
Alternative Names: COVID-19;SARS-CoV-2; 2019-nCoV
Assay Type: Sandwich
Sensitivity: 3.1 pg/mL
Standard: 500 pg/mL
Detection Range: 7.82-500 pg/mL
Sample Type: serum, plasma, saliva, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
Assay Length: 3.5h
Research Area: Infectious Diseases
Test principle: The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Human SARS-CoV-2 Nucleocapsid. Standards or samples are added to the appropriate microtiter plate wells then with a biotin-conjugated antibody specific to Human SARS-CoV-2 Nucleocapsid. Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Human SARS-CoV-2 Nucleocapsid, biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Human SARS-CoV-2 Nucleocapsid in the samples is then determined by comparing the OD of the samples to the standard curve.

Standard curve

Concentration (pg/mL) OD Corrected OD
500.00 2.248 2.103
250.00 1.668 1.523
125.00 1.078 0.933
62.50 0.665 0.520
31.25 0.429 0.284
15.63 0.323 0.178
7.82 0.236 0.091
0.00 0.145 0.000

Precision

Intra-assay Precision (Precision within an assay):CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays):CV%<10%

Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.

Recovery

Matrices listed below were spiked with certain level of recombinant SARS-CoV-2 Nucleocapsid and the recovery rates were calculated by comparing the measured value to the expected amount of SARS-CoV-2 Nucleocapsid in samples.
Matrix Recovery range Average
serum(n=5) 90-105% 97%
EDTA plasma(n=5) 79-97% 88%
Heparin plasma(n=5) 80-92% 86%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of SARS-CoV-2 Nucleocapsid and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Matrix 1:2 1:4 1:8 1:16
serum(n=5) 95-105% 88-102% 95-102% 87-98%
EDTA plasma(n=5) 79-96% 85-99% 98-105% 92-101%
Heparin plasma(n=5) 85-105% 92-104% 95-102% 86-97%